Genasense oblimerson: Phase II final data

In an open-label, single-arm, U.S. Phase II trial in 49 patients, Genasense injection

Read the full 134 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE